自和生物转化会影响肝细胞癌中的索拉芬尼抗性
Ruiqi Zheng1, Shuang Weng2, Jianping Xu3
1State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Computational and structural biotechnology journal
|July 31, 2023
概括
治疗前的因素如PI3K/AKT激活,生物转化和自会影响肝细胞癌 (HCC) 患者对索拉费尼布的反应. 关键分子ADH1A和STING1与索拉费尼布耐药性有关,这表明新的治疗点.
科学领域:
- 在瘤学瘤学.
- 蛋白质组学是指蛋白质组学.
- 分子生物学分子生物学
背景情况:
- 索拉菲尼布是晚期肝细胞癌 (HCC) 的首要治疗方法.
- 索拉费尼布耐药性是一个重大的临床挑战,大多数研究都集中在治疗后的耐药性机制上.
- 了解影响索拉费尼布敏感性的治疗前因素对于改善患者的治疗结果至关重要.
研究的目的:
- 使用蛋白质组技术,研究潜在的预治疗因素,影响肝细胞癌中索拉芬尼抗性.
- 在开始治疗之前,确定参与索拉芬尼布耐药性的关键分子参与者.
主要方法:
- 肝细胞癌患者样本的蛋白质组分析.
- 研究途径激活 (PI3K/AKT),生物转化能力和自水平.
- 识别关键分子,例如ADH1A和STING1.
主要成果:
- 预处理PI3K/AKT通路激活,生物转化能力和自水平与HCC中索拉芬尼抗性有关.
- 鉴定出ADH1A和STING1是影响索拉费尼布敏感性的关键分子.
- 这些因素相互作用促进瘤细胞存活,并与HCC预后有关.
结论:
- 治疗前的细胞状态,包括PI3K/AKT激活,生物转化和自,显著影响HCC中索拉芬尼的疗效.
- 向ADH1A和STING1可能为克服索拉芬尼布耐药性提供新的治疗策略.
- 研究结果表明,免疫疗法有可能改善 sorafenib 耐药 HCC 患者的存活率.
相关概念视频
Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Factors Affecting Drug Biotransformation: Biological
178
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
178
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


